US20180228214A1 - Container containing a nicotine solution - Google Patents

Container containing a nicotine solution Download PDF

Info

Publication number
US20180228214A1
US20180228214A1 US15/525,163 US201515525163A US2018228214A1 US 20180228214 A1 US20180228214 A1 US 20180228214A1 US 201515525163 A US201515525163 A US 201515525163A US 2018228214 A1 US2018228214 A1 US 2018228214A1
Authority
US
United States
Prior art keywords
nicotine
acid
solution
protonated
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US15/525,163
Inventor
Kevin Gerard McAdam
Connor BRUTON
Marina Trani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicoventures Trading Ltd
Original Assignee
Nicoventures Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180228214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicoventures Holdings Ltd filed Critical Nicoventures Holdings Ltd
Assigned to NICOVENTURES HOLDINGS LIMITED reassignment NICOVENTURES HOLDINGS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRUTON, Connor, MCADAM, KEVIN GERARD, TRANI, MARINA
Publication of US20180228214A1 publication Critical patent/US20180228214A1/en
Assigned to Nicoventures Trading Limited reassignment Nicoventures Trading Limited ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NICOVENTURES HOLDINGS LIMITED
Pending legal-status Critical Current

Links

Images

Classifications

    • A24F47/008
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24FSMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40Constructional details, e.g. connection of cartridges and battery parts
    • A24F40/42Cartridges or containers for inhalable precursors
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10Chemical features of tobacco products or tobacco substitutes
    • A24B15/16Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10Chemical features of tobacco products or tobacco substitutes
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10Chemical features of tobacco products or tobacco substitutes
    • A24B15/16Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18Treatment of tobacco products or tobacco substitutes
    • A24B15/28Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24FSMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10Devices using liquid inhalable precursors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/06Inhaling appliances shaped like cigars, cigarettes or pipes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2023/00Use of polyalkenes or derivatives thereof as moulding material
    • B29K2023/10Polymers of propylene
    • B29K2023/12PP, i.e. polypropylene
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2069/00Use of PC, i.e. polycarbonates or derivatives thereof, as moulding material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29LINDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00Other particular articles
    • B29L2031/712Containers; Packaging elements or accessories, Packages
    • B29L2031/7142Aerosol containers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29LINDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00Other particular articles
    • B29L2031/7414Smokers'' requisites, e.g. pipe cleaners
    • B29L2031/7416Smokers'' requisites, e.g. pipe cleaners for cigars or cigarettes

Definitions

  • the present disclosure relates to containers which contain a nicotine solution and to electronic vapor provision systems such as electronic nicotine delivery systems (e.g. e-cigarettes) incorporating such containers.
  • electronic nicotine delivery systems e.g. e-cigarettes
  • Electronic vapor provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporized, typically containing nicotine.
  • a heater is activated to vaporize a small amount of liquid, which is therefore inhaled by the user.
  • the liquid to be vaporized in e-cigarettes is typically a solution containing nicotine.
  • the solvent may be, for example, glycerol.
  • the vaporizing part of the device is often designed for multiple uses, although single use devices do exist. In multiple and single use devices a container holding the nicotine solution is present. The container is stored for significant periods from the time of filling until use. This period includes the time of distribution, stocking by a retailer and storage by the end user before use. During this storage period, loss of nicotine content may occur.
  • a contained nicotine solution comprising: (i) a container; and (ii) a nicotine solution contained within the container, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • an electronic vapor provision system comprising: a vaporizer for vaporizing liquid for inhalation by a user of the electronic vapor provision system; a power supply comprising a cell or battery for supplying power to the vaporizer; a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • a process for stabilizing a nicotine solution comprising: protonating the nicotine present in the solution such that at least 5 wt % of the nicotine present in the solution is in protonated form.
  • FIG. 1 shows a graph
  • the present disclosure relates to a container which may be used in an electronic vapor provision system, such as an e-cigarette.
  • an electronic vapor provision system such as an e-cigarette.
  • e-cigarette is used; however, this term may be used interchangeably with electronic vapor provision system.
  • nicotine may exist in free base form, monoprotonated form or diprotonated form.
  • monoprotonated form may exist in free base form, monoprotonated form or diprotonated form.
  • the structures of each of these forms are given below.
  • Reference in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form means the combined amount of monoprotonated nicotine and diprotonated nicotine.
  • the present disclosure provides a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • Nicotine 3-(1-methylpyrrolidin-2-yl) pyridine
  • pKa 3.12 for the pyridine ring
  • 8.02 for the pyrrolidine ring. It can exist in pH-dependent protonated (mono- and di-) and non-protonated forms which have different bioavailability.
  • the fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di- depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
  • the relative fraction of protonated nicotine in solution can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems.
  • [B] is the amount of non-protonated nicotine (i.e. free base)
  • [BH+] the amount of protonated nicotine (i.e. conjugate acid)
  • the relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
  • Determination of pKa values of nicotine solutions may be was carried out using the basic approach described in “Spectroscopic investigations into the acid-base properties of nicotine at different temperatures”, Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, .Anal. Methods, 2013, 5, 81-88. This method is summarized below.
  • polycarbonate it is meant a polymer containing the following repeating unit
  • At least a portion of the container in contact with the nicotine solution is formed from polycarbonate. In one aspect the majority of the container which is in contact with the nicotine solution is formed from polycarbonate. In one aspect all the container which is in contact with the nicotine solution is formed from polycarbonate. In one aspect the container is formed entirely from polycarbonate.
  • polypropylene it is meant a polymer containing the following repeating unit
  • At least a portion of the container in contact with the nicotine solution is formed from polypropylene. In one aspect the majority of the container which is in contact with the nicotine solution is formed from polypropylene. In one aspect all the container which is in contact with the nicotine solution is formed from polypropylene. In one aspect the container is formed entirely from polypropylene.
  • the majority of the container which is in contact with the nicotine solution is formed from polycarbonate, polypropylene or a combination thereof. In one aspect all the container which is in contact with the nicotine solution is formed from polycarbonate, polypropylene or a combination thereof. In one aspect the container is formed entirely from polycarbonate, polypropylene or a combination thereof.
  • the container of the present disclosure is typically provided for the delivery of nicotine solution to or within an e-cigarette.
  • the nicotine solution may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette.
  • e-cigarettes typically contain a unit known as a cartomizer which comprises a reservoir of nicotine solution, a wick material and a heating element for vaporizing the nicotine.
  • the container is a cartomizer or is part of a cartomizer.
  • the container is not a cartomizer or part of a cartomizer and is a container, such as a tank, bottle or the like, which may be used to deliver nicotine solution to or within an e-cigarette.
  • the container is part of an e-cigarette. Therefore in a further aspect the present disclosure provides an electronic vapor provision system comprising: a vaporizer for vaporizing liquid for inhalation by a user of the electronic vapor provision system; a power supply comprising a cell or battery for supplying power to the vaporizer; a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • contact may occur between the container and the nicotine solution by any means. Provided the body of the container is contacted with nicotine solution then the container and solution are in contact. It is envisaged that the nicotine solution could be ‘free’ in the sense that it is a liquid in direct contact with the walls of the container. In also envisaged, that the nicotine solution may be held within a matrix (such as a foam) and the foam is in contact with the body of the container.
  • a matrix such as a foam
  • the nicotine present in the solution is in protonated form. In one aspect at least 15 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 20 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 25 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 30 wt % of the nicotine present in the solution is in protonated form.
  • At least 35 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 40 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 45 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 50 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 55 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 60 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 65 wt % of the nicotine present in the solution is in protonated form.
  • At least 70 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 75 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 80 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 85 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 90 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 95 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 99 wt % of the nicotine present in the solution is in protonated form.
  • the nicotine protonation may be provided in such a manner to achieve the desired degree of protonation of nicotine.
  • the nicotine is protonated by an organic acid.
  • the nicotine is protonated by a carboxylic acid.
  • the carboxylic acid may be any suitable carboxylic acid.
  • the nicotine is protonated by a mono-carboxylic acid.
  • the nicotine is protonated by an acid selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
  • an acid selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
  • the nicotine is protonated by an acid selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof In one aspect the nicotine is protonated by levulinic acid. In one aspect the nicotine is protonated by benzoic acid. In one aspect the nicotine is protonated by a mixture of levulinic acid and benzoic acid.
  • Nicotine may exist in free base form, monoprotonated form or diprotonated form. As discussed herein we have found that by protonating at least some of the nicotine present in a solution, the stability of the nicotine solution may be enhanced. We have found that solutions of nicotine when stored for significant periods suffer loss of nicotine content. Although problems of stability are particularly observed when nicotine solution is stored in contact with polycarbonate or polypropylene, the problems are not exclusive to those materials.
  • the present disclosure therefore provides a novel process for stabilizing a nicotine solution.
  • the present disclosure provides a process for stabilizing a nicotine solution, the process comprising the steps of protonating the nicotine present in the solution such that at least 5 wt % of the nicotine present in the solution is in protonated form.
  • the nicotine solution may be in contact with polycarbonate or polypropylene.
  • the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 7 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 14 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 21 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 28 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 2 months.
  • the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 3 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 4 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 5 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 6 months.
  • the present disclosure further provides a novel use for stabilizing a nicotine solution.
  • the present disclosure provides use of protonation of nicotine for stabilizing a nicotine solution.
  • the present disclosure provides use of protonation of nicotine for improving storage stability of a nicotine solution.
  • the present disclosure provides use of protonation of nicotine for reducing evaporative loss of nicotine from a nicotine solution.
  • the present disclosure provides use of protonated nicotine for stabilizing a solution containing nicotine free base. In one aspect the present disclosure provides use of protonated nicotine for improving storage stability of a solution containing nicotine free base. In one aspect the present disclosure provides use of protonated nicotine for reducing evaporative loss of nicotine from a nicotine free base solution. It will be understood that by ‘nicotine free base solution’ it may be meant a solution containing nicotine free base and protonated nicotine in an amount as described herein.
  • the present disclosure provides use of an acid for stabilizing a nicotine solution. In one aspect the present disclosure provides use of an acid for improving storage stability of a nicotine solution.
  • the acid is an organic acid. In one aspect of use in accordance with the present disclosure the acid is a carboxylic acid. In one aspect of use in accordance with the present disclosure the acid is a mono-carboxylic acid.
  • the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
  • the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof.
  • the acid is levulinic acid.
  • the acid is benzoic acid.
  • the acid is a mixture of levulinic acid and benzoic acid.
  • the present disclosure provides use of an acid for stabilizing a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof.
  • the present disclosure provides use of an acid for improving storage stability of a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof.
  • the present disclosure provides use of an acid for reducing evaporative loss of nicotine from a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof.
  • At least 5 wt % of the nicotine present in the nicotine solution may be in protonated form.
  • the present disclosure provides use of protonation of nicotine for stabilizing a nicotine solution with respect to polycarbonate or polypropylene. In one aspect the present disclosure provides use of protonation of nicotine for improving storage stability of a nicotine solution with respect to polycarbonate or polypropylene.
  • UV absorbance & CD spectra were measured between 300-200 nm region, with various pathlengths depending upon the nicotine concentration of the solution—10 mm, 5 mm, 2 mm, 1 mm, 0.5 mm, 0.1 mm and 0.01 mm pathlengths.
  • the instrument was flushed continuously with pure evaporated nitrogen throughout the measurements. Throughout measurements spectra were recorded with a 0.5 nm step size, a 1 s measurement time-per-point and a spectral bandwidth of 2 nm. Where possible, all CD spectra were smoothed with a window factor of 4 using the Savitzky-Golay method for better presentation.
  • Solutions of S-Nicotine in glycerol/water were pH titrated at 23° C. The pH of these solutions was raised towards alkaline by adding small aliquots of NaOH ( ⁇ pH10) and then lowered to pH2 by adding small aliquots of HCl. A series of 0.1M, 0.5M, 1M, 5M and 10M of HCl and NaOH solutions were used during the pH titration. pHs were measured at 23° C. using a Corning pH105 pH meter with a RMS pH electrode. The p s K a2 values changed systematically with nicotine concentration ( FIG. 1 ) and therefore values for p s K a2 were calculated at each nicotine concentration level (Table 1).
  • Use of this p s K a2 value with the Henderson-Hasselbalch equation allows calculation of the degree of nicotine protonationm at any pH value.
  • Example 1 The materials were formulated as described and the pH determined as described in Example 1. Based on the pKa of 7.26 determined in Example 1, the percentage of nicotine that was protonated was calculated using the Henderson-Hasselbalch equation. The results obtained are tabulated below.
  • the absorption of nicotine by a number of materials suitable for use in e-cigarettes was studied. The objective of this study was to determine whether there was any absorption of nicotine from a liquid formulation into a variety of materials occurring over time.
  • 5 g of a nicotine solution comprising 3.7 wt % nicotine, 9% water and 87.3% glycerol was loaded into 40m1 amber glass vials.
  • Pieces of polypropylene and polycarbonate were added to solutions (except for control samples), the vials were sealed with screw caps and stored at ambient temperatures or at 40° C. in an oven for a period of eight weeks. Sampling was performed on day 1, then at 1 week, 2 weeks, 4 weeks and 8 weeks.
  • polypropylene (PP) and polycarbonate (PC) both of which are desirable materials for use in e-cigarettes were found to result in significant loss of nicotine when stored in contact with a nicotine solution containing nicotine only in free base form.
  • the effect on storage stability of protonating nicotine was studied by examining 3 nicotine solutions loaded into cartomizer e-cigarettes (“Device”) containing PP and PC.
  • the three nicotine solutions were an acid free nicotine solution and two protonated solutions, one protonated with 1.0 Molar equivalent levulinic acid and one protonated with 1.0 Molar equivalent benzoic acid.
  • a 2.5% w/w nicotine amount was used, together with 9% water and sufficient glycerol to make the solution to 100%.
  • the stability protocol incorporated filling a series of e-cigarettes for each formulation, as well as loading a number of sealed glass vials (used as control samples) to understand the source of any observed nicotine losses.
  • the e-cigarettes were puffed on a 20-channel linear smoking machine (SM450) compliant with ISO 3308, but using the following puffing parameters: 80 ml puff volume, 3 second puff duration and 30 second interpuff interval.
  • SM450 20-channel linear smoking machine
  • Each port of the smoking engine was fitted with a holder containing a Cambridge filter (CF) pad to trap particulate matter.
  • TPM was determined as the weight difference of the CF before and after puffing, in accordance with ISO 4387.
  • the CF pad containing trapped aerosol was extracted into 20 ml high purity propan-2-ol containing appropriate internal standards. Nicotine and water were determined by GC analysis containing combined FID/TCD detectors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Filling, Topping-Up Batteries (AREA)

Abstract

There is provided a contained nicotine solution comprising (i) a container; and (ii) a nicotine solution contained within the container, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a National Phase entry of PCT Application No. PCT/GB2015/053369, filed Nov. 6, 2015, which claims priority from GB Patent Application No. 1419866.7, filed Nov. 7, 2014, each of which is hereby fully incorporated herein by reference in its entirety.
  • TECHNICAL FIELD
  • The present disclosure relates to containers which contain a nicotine solution and to electronic vapor provision systems such as electronic nicotine delivery systems (e.g. e-cigarettes) incorporating such containers.
  • BACKGROUND
  • Electronic vapor provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporized, typically containing nicotine. When a user inhales on the device, a heater is activated to vaporize a small amount of liquid, which is therefore inhaled by the user.
  • The use of e-cigarettes in the UK has grown rapidly, and it has been estimated that there are now over a million people using them in the UK.
  • The liquid to be vaporized in e-cigarettes is typically a solution containing nicotine. The solvent may be, for example, glycerol. The vaporizing part of the device is often designed for multiple uses, although single use devices do exist. In multiple and single use devices a container holding the nicotine solution is present. The container is stored for significant periods from the time of filling until use. This period includes the time of distribution, stocking by a retailer and storage by the end user before use. During this storage period, loss of nicotine content may occur.
  • SUMMARY
  • In one aspect there is provided a contained nicotine solution comprising: (i) a container; and (ii) a nicotine solution contained within the container, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • In one aspect there is provided an electronic vapor provision system comprising: a vaporizer for vaporizing liquid for inhalation by a user of the electronic vapor provision system; a power supply comprising a cell or battery for supplying power to the vaporizer; a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • In one aspect there is provided a process for stabilizing a nicotine solution, the process comprising: protonating the nicotine present in the solution such that at least 5 wt % of the nicotine present in the solution is in protonated form.
  • In one aspect there is provided use of protonation of nicotine for stabilizing a nicotine solution.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Embodiments will now be described with reference to the following non-limiting examples and with reference to the accompanying figure, in which:
  • FIG. 1 shows a graph.
  • DETAILED DESCRIPTION
  • As described above, the present disclosure relates to a container which may be used in an electronic vapor provision system, such as an e-cigarette. Throughout the following description the term “e-cigarette” is used; however, this term may be used interchangeably with electronic vapor provision system.
  • We have found that by protonating at least some of the nicotine present in a solution, the stability of the nicotine solution may be enhanced. We have found that solutions of nicotine when stored for significant periods suffer loss of nicotine content. By protonating at least a portion of the nicotine, and specifically at least 5 wt. % of the nicotine present, loss of the nicotine during storage is reduced. It has been found that loss of nicotine is particularly observed when nicotine solution is stored in contact with polycarbonate or polypropylene. These materials are desirable for use in -e-cigarettes due to their cost and their feel when held by a user. However, loss of nicotine may prohibit their use without the stabilization of nicotine provided by the present disclosure.
  • As is understood by one skilled in the art, nicotine may exist in free base form, monoprotonated form or diprotonated form. The structures of each of these forms are given below.
  • Figure US20180228214A1-20180816-C00001
  • Reference in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form means the combined amount of monoprotonated nicotine and diprotonated nicotine.
  • For ease of reference, these and further aspects of the present disclosure are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
  • The present disclosure provides a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • The relevant amounts of nicotine which are present in the solution in protonated form are specified herein. These amounts may be readily calculated by one skilled in the art. Nicotine, 3-(1-methylpyrrolidin-2-yl) pyridine, is a diprotic base with pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring. It can exist in pH-dependent protonated (mono- and di-) and non-protonated forms which have different bioavailability.
  • The distribution of protonated and non-protonated nicotine will vary at various pH increments.
  • Figure US20180228214A1-20180816-C00002
  • The fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di- depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
  • The relative fraction of protonated nicotine in solution can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems. Consider the following equilibrium:

  • B+H+
    Figure US20180228214A1-20180816-P00002
    BH+
  • The Henderson-Hasselbalch equation for this equilibrium is:
  • pH = pKa + log [ B ] [ BH + ]
  • Where [B] is the amount of non-protonated nicotine (i.e. free base), [BH+] the amount of protonated nicotine (i.e. conjugate acid) and pKa is the reference pKa value for the pyrrolidine ring nitrogen of nicotine (pKa=8.02). The relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
  • % protonated nicotine = 100 - { [ B ] [ BH + ] { 1 + [ B ] [ BH + ] } * 100 }
  • Determination of pKa values of nicotine solutions may be was carried out using the basic approach described in “Spectroscopic investigations into the acid-base properties of nicotine at different temperatures”, Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, .Anal. Methods, 2013, 5, 81-88. This method is summarized below.
  • As will be understood by one skilled in the art, by polycarbonate it is meant a polymer containing the following repeating unit
  • Figure US20180228214A1-20180816-C00003
  • In one aspect at least a portion of the container in contact with the nicotine solution is formed from polycarbonate. In one aspect the majority of the container which is in contact with the nicotine solution is formed from polycarbonate. In one aspect all the container which is in contact with the nicotine solution is formed from polycarbonate. In one aspect the container is formed entirely from polycarbonate.
  • As will be understood by one skilled in the art, by polypropylene it is meant a polymer containing the following repeating unit
  • Figure US20180228214A1-20180816-C00004
  • In one aspect at least a portion of the container in contact with the nicotine solution is formed from polypropylene. In one aspect the majority of the container which is in contact with the nicotine solution is formed from polypropylene. In one aspect all the container which is in contact with the nicotine solution is formed from polypropylene. In one aspect the container is formed entirely from polypropylene.
  • In one aspect the majority of the container which is in contact with the nicotine solution is formed from polycarbonate, polypropylene or a combination thereof. In one aspect all the container which is in contact with the nicotine solution is formed from polycarbonate, polypropylene or a combination thereof. In one aspect the container is formed entirely from polycarbonate, polypropylene or a combination thereof.
  • As discussed herein, the container of the present disclosure is typically provided for the delivery of nicotine solution to or within an e-cigarette. The nicotine solution may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette. As understood by one skilled in the art, e-cigarettes typically contain a unit known as a cartomizer which comprises a reservoir of nicotine solution, a wick material and a heating element for vaporizing the nicotine. In one aspect the container is a cartomizer or is part of a cartomizer. In one aspect the container is not a cartomizer or part of a cartomizer and is a container, such as a tank, bottle or the like, which may be used to deliver nicotine solution to or within an e-cigarette.
  • In one aspect the container is part of an e-cigarette. Therefore in a further aspect the present disclosure provides an electronic vapor provision system comprising: a vaporizer for vaporizing liquid for inhalation by a user of the electronic vapor provision system; a power supply comprising a cell or battery for supplying power to the vaporizer; a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
  • As will be understood by one skilled in the art, contact may occur between the container and the nicotine solution by any means. Provided the body of the container is contacted with nicotine solution then the container and solution are in contact. It is envisaged that the nicotine solution could be ‘free’ in the sense that it is a liquid in direct contact with the walls of the container. In also envisaged, that the nicotine solution may be held within a matrix (such as a foam) and the foam is in contact with the body of the container.
  • As discussed herein, we have found that by protonating at least a portion of the nicotine, and specifically at least 5 wt. % of the nicotine present, loss of the nicotine during storage is reduced. In one aspect at least 10 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 15 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 20 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 25 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 30 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 35 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 40 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 45 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 50 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 55 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 60 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 65 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 70 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 75 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 80 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 85 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 90 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 95 wt % of the nicotine present in the solution is in protonated form. In one aspect at least 99 wt % of the nicotine present in the solution is in protonated form.
  • The nicotine protonation may be provided in such a manner to achieve the desired degree of protonation of nicotine. In one aspect the nicotine is protonated by an organic acid. In one aspect the nicotine is protonated by a carboxylic acid. The carboxylic acid may be any suitable carboxylic acid. In one aspect the nicotine is protonated by a mono-carboxylic acid.
  • In one aspect the nicotine is protonated by an acid selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
  • In one aspect the nicotine is protonated by an acid selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof In one aspect the nicotine is protonated by levulinic acid. In one aspect the nicotine is protonated by benzoic acid. In one aspect the nicotine is protonated by a mixture of levulinic acid and benzoic acid.
  • Nicotine may exist in free base form, monoprotonated form or diprotonated form. As discussed herein we have found that by protonating at least some of the nicotine present in a solution, the stability of the nicotine solution may be enhanced. We have found that solutions of nicotine when stored for significant periods suffer loss of nicotine content. Although problems of stability are particularly observed when nicotine solution is stored in contact with polycarbonate or polypropylene, the problems are not exclusive to those materials. The present disclosure therefore provides a novel process for stabilizing a nicotine solution. The present disclosure provides a process for stabilizing a nicotine solution, the process comprising the steps of protonating the nicotine present in the solution such that at least 5 wt % of the nicotine present in the solution is in protonated form.
  • In the process of the present disclosure the nicotine solution may be in contact with polycarbonate or polypropylene.
  • We have found that extended periods of storage are possible with the practice of the present disclosure. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 7 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 14 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 21 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 28 days. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 2 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 3 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 4 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 5 months. In one aspect the process provides for storage of the nicotine solution in contact with polycarbonate or polypropylene for a period of at least 6 months.
  • The present disclosure further provides a novel use for stabilizing a nicotine solution. In one aspect the present disclosure provides use of protonation of nicotine for stabilizing a nicotine solution. In one aspect the present disclosure provides use of protonation of nicotine for improving storage stability of a nicotine solution. In one aspect the present disclosure provides use of protonation of nicotine for reducing evaporative loss of nicotine from a nicotine solution.
  • In one aspect the present disclosure provides use of protonated nicotine for stabilizing a solution containing nicotine free base. In one aspect the present disclosure provides use of protonated nicotine for improving storage stability of a solution containing nicotine free base. In one aspect the present disclosure provides use of protonated nicotine for reducing evaporative loss of nicotine from a nicotine free base solution. It will be understood that by ‘nicotine free base solution’ it may be meant a solution containing nicotine free base and protonated nicotine in an amount as described herein.
  • In one aspect the present disclosure provides use of an acid for stabilizing a nicotine solution. In one aspect the present disclosure provides use of an acid for improving storage stability of a nicotine solution. In one aspect of use in accordance with the present disclosure the acid is an organic acid. In one aspect of use in accordance with the present disclosure the acid is a carboxylic acid. In one aspect of use in accordance with the present disclosure the acid is a mono-carboxylic acid. In one aspect of use in accordance with the present disclosure the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof. In one aspect of use in accordance with the present disclosure the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof. In one aspect of use in accordance with the present disclosure the acid is levulinic acid. In one aspect of use in accordance with the present disclosure the acid is benzoic acid. In one aspect of use in accordance with the present disclosure the acid is a mixture of levulinic acid and benzoic acid.
  • In one aspect the present disclosure provides use of an acid for stabilizing a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof. In one aspect the present disclosure provides use of an acid for improving storage stability of a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof. In one aspect the present disclosure provides use of an acid for reducing evaporative loss of nicotine from a nicotine solution, wherein the acid is selected from the group consisting of benzoic acid, levulinic acid, and mixtures thereof.
  • In the use aspects of the present disclosure at least 5 wt % of the nicotine present in the nicotine solution may be in protonated form.
  • In one aspect the present disclosure provides use of protonation of nicotine for stabilizing a nicotine solution with respect to polycarbonate or polypropylene. In one aspect the present disclosure provides use of protonation of nicotine for improving storage stability of a nicotine solution with respect to polycarbonate or polypropylene.
  • EXAMPLES Example 1 Determination of pKa Values
  • The determination of pKa values of nicotine in glycerol/water systems was carried out using the basic approach described in “Spectroscopic investigations into the acid-base properties of nicotine at different temperatures”, Peter M. Clayton, Carl A. Vas, Tam T. T. Bui, Alex F. Drake and Kevin McAdam, Anal. Methods, 2013, 5, 81-88, and summarized below. Because the system is predominantly non-aqueous the parameter psKa2 was measured, where subscript s refers to the solvent composition in this largely non-aqueous system, and subscript 2 refers to the pKa value of the pyrrolidyl nitrogen.
  • Further information on the determination of pKa values of nicotine in e-cigarette solutions is provided in “Use of chiroptical spectroscopy to determine the ionisation status of (S)-nicotine in e-cigarette formulations and snus”, Clayton et al, ST 49, CORESTA Congress, Québec City, Canada, 12-16 Oct. 2014 (available at http://www.bat-science.com/groupms/sites/BAT_9GVJXS.nsf/vwPagesWebLive/DO9PVC3G/$FILE/CORE STA_PC_2014.pdf).
  • A range of glycerol/water/nicotine solutions were prepared, with the water concentration fixed at 9%, the nicotine concentration varying from 30 μg/ml to 3 mg/ml; and the glycerol content comprising the remainder of the solutions.
  • Simultaneous UV & CD spectra of glycerol/s-nicotine/water solutions were measured on the Applied Photophysics Ltd (Leatherhead, UK) Chiracsan Plus spectrometer. The UV absorbance & CD spectra were measured between 300-200 nm region, with various pathlengths depending upon the nicotine concentration of the solution—10 mm, 5 mm, 2 mm, 1 mm, 0.5 mm, 0.1 mm and 0.01 mm pathlengths. The instrument was flushed continuously with pure evaporated nitrogen throughout the measurements. Throughout measurements spectra were recorded with a 0.5 nm step size, a 1 s measurement time-per-point and a spectral bandwidth of 2 nm. Where possible, all CD spectra were smoothed with a window factor of 4 using the Savitzky-Golay method for better presentation.
  • Solutions of S-Nicotine in glycerol/water were pH titrated at 23° C. The pH of these solutions was raised towards alkaline by adding small aliquots of NaOH (˜pH10) and then lowered to pH2 by adding small aliquots of HCl. A series of 0.1M, 0.5M, 1M, 5M and 10M of HCl and NaOH solutions were used during the pH titration. pHs were measured at 23° C. using a Corning pH105 pH meter with a RMS pH electrode. The psKa2 values changed systematically with nicotine concentration (FIG. 1) and therefore values for psKa2 were calculated at each nicotine concentration level (Table 1). Due to the viscosity of the solutions, and the optical density in the CD spectra of the high nicotine concentration solutions, very small path-length cells were required for nicotine concentrations above 3 mg/ml. Satisfactory sample preparation and spectroscopy could not be achieved with the necessary small cells at these concentrations, and therefore the psKa2 at higher concentrations were calculated from a regression fit to FIG. 1.
  • TABLE 1
    psKa2 values measured at various nicotine concentrations
    in a 9% water, nicotine/glycerol system.
    conc
    psKa2 conc g/L) (mM) log10 [conc]
    7.49 0.03 0.185 −0.732
    7.34 0.06 0.370 −0.431
    7.30 0.3 1.85 0.268
    7.27 0.6 3.70 0.569
    7.25 3 18.53 1.268
  • Curve fitting, using the equation y=0.0233e(−(log 10[nicotine])/0.325)+7.26 provided a psKa2 value of 7.26 at 30 mg/ml nicotine concentration. Use of this psKa2 value with the Henderson-Hasselbalch equation allows calculation of the degree of nicotine protonationm at any pH value.
  • Example 2 Determination of pH and % Protonation
  • The materials were formulated as described and the pH determined as described in Example 1. Based on the pKa of 7.26 determined in Example 1, the percentage of nicotine that was protonated was calculated using the Henderson-Hasselbalch equation. The results obtained are tabulated below.
  • Formation composition (% w/w)
    PG + Benzoic
    flavor acid Levulinic Average Average %
    Formulation Nicotine Glycerol Water level level acid level Flavors pH Temp (° C.) protonated
    4% w/w Nicotine in glycerol/water 4 87 9 0 0.00 0.00 not present 9.21 22.1 1.1
    4% w/w Nicotine in 4 62.00 9 25 0.00 0.00 not present 9.18 21.8 1.2
    glycerol/water/PG
    4% w/w Nicotine + Cherry flavor 4 62.00 9 25 0.00 0.00 present 8.23 22.7 9.7
    4% w/w Nicotine + Cherry flavor + 4 60.80 9 25 1.20 0.00 present 7.16 21.0 55.7
    0.4M Benzoic Acid
    4% w/w Nicotine + Cherry flavor + 4 60.85 9 25 0.00 1.15 present 6.99 21.0 65.1
    0.4M Levulinic Acid
    1.8% w/w Nicotine + glycerol/water 1.86 89.2 9 0 0.00 0.00 not present 9.32 22.2 0.9
    1.8% w/w Nicotine in 1.86 42.2 25 25 0.00 0.00 not present 9.21 22.2 1.1
    glycerol/water/PG
    1.8% w/w Nicotine + Cherry flavor 1.86 42.2 25 25 0.00 0.00 present 8.14 21.2 11.6
    1.8% w/w Nicotine + Cherry flavor + 1.86 47.59 25 25 0.55 0.00 present 7.34 21.3 45.4
    0.4M Benzoic Acid
    1.8% w/w Nicotine + Cherry + 0.4M 1.86 47.62 25 25 0.00 0.52 present 7.08 21.2 60.2
    Levulinic Acid
    4% w/w Nicotine in glycerol/water 4 87 9 0 0.00 0.00 not present 9.21 22.1 1.1
    4% w/w Nicotine in 4 52 9 35 0.00 0.00 not present 9.11 22.4 1.4
    glycerol/water/PG
    4% w/w Nicotine + Menthol 4 50.5 9 36.5 0.00 0.00 present 9.36 22.3 0.8
    4% w/w Nicotine + Menthol + 0.4M 4 49.3 9 36.5 1.20 0.00 present 6.95 21.1 67.1
    Benzoic Acid
    4% w/w Nicotine + Menthol + 0.4M 4 49.35 9 36.5 0.00 1.15 present 6.81 21.1 73.8
    Levulinic Acid
    1.8% w/w Nicotine in glycerol/water 1.86 89.2 9 0 0.00 0.00 not present 9.32 22.2 0.9
    1.8% w/w Nicotine in 1.86 38.14 25 35 0.00 0.00 not present 9.08 22.7 1.5
    glycerol/water/PG
    1.8% w/w Nicotine + Menthol 1.86 36.64 25 36.5 0.00 0.00 present 9.07 21.2 1.5
    1.8% w/w Nicotine + Menthol + 1.86 36.09 25 36.5 0.55 0.00 present 7.13 21.1 57.4
    0.4M Benzoic Acid
    1.8% w/w Nicotine + Menthol + 1.86 36.145 25 36.5 0.00 0.50 present 6.95 21.4 67.1
    0.4M Levulinic Acid
    1.8% Nicotine, 25% Water, 25% PG 1.8 48.2 25 25 0.00 0.00 present 8.5 5.4
    with Tobacco flavor “A”
    1.8% Nicotine, 25% Water, 25% PG 1.8 47.79 25 25 0.41 0.00 present 7.4 42.0
    with Tobacco flavor “A”, 0.3 Molar
    equivalent Benzoic
    1.8% Nicotine, 25% Water, 25% PG 1.8 47.17 25 25 1.03 0.00 present 6.8 74.3
    with Tobacco flavor “A” 0.75 Molar
    equivalent Benzoic
    N/N—H: Nicotine/Protonated nicotine
    PG: propylene glycol
  • Example 3 Storage Stability of Nicotine in Solutions Exposed to PP and PC
  • The absorption of nicotine by a number of materials suitable for use in e-cigarettes was studied. The objective of this study was to determine whether there was any absorption of nicotine from a liquid formulation into a variety of materials occurring over time. 5 g of a nicotine solution comprising 3.7 wt % nicotine, 9% water and 87.3% glycerol was loaded into 40m1 amber glass vials. Pieces of polypropylene and polycarbonate were added to solutions (except for control samples), the vials were sealed with screw caps and stored at ambient temperatures or at 40° C. in an oven for a period of eight weeks. Sampling was performed on day 1, then at 1 week, 2 weeks, 4 weeks and 8 weeks.
  • An accurately weighed aliquot of solution was removed from the vials using a Pasteur pipette and diluted with water (˜40 mg sample in 1 ml). The final solution weights were also recorded. Analysis for nicotine was performed by LC-UV using a Waters Acquity LC system incorporating a Diode Array detector.
  • All analyses were performed using a 1000 ppm external nicotine standard prepared in water. Linearity of analysis of nicotine was checked at each time-point with 500 ppm, 1000 ppm and 2000 ppm standards.
  • Time-Point Time in Storage Analysis Date
  • T = 0 1 day
    T = 1 1 week
    T = 2 2 weeks
    T = 4 4 weeks
    T = 8 8 weeks
  • The findings are reported below in tabulated format.
  • Container Temp T = 0 T = 1 T = 2 T = 3 T = 4
    Control Ambient wt % 4.16 4.17 4.10 4.06 3.84
    Nicotine
    % loss 0.25 −1.51 −2.39 −7.71
    Control 40° C. wt % 4.16 4.18 4.05 4.10 3.97
    Nicotine
    % loss 0.41 −2.62 −1.38 −4.68
    PP Ambient wt % 4.20 4.16 4.03 4.07 3.61
    Nicotine
    % loss −0.92 −3.98 −3.18 −14.05
    PP 40° C. wt % 4.27 4.09 3.96 3.94 3.70
    Nicotine
    % loss −4.24 −7.35 −7.80 −13.37
    PC Ambient wt % 4.10 4.10 4.12 4.01 3.58
    Nicotine
    % loss 0.03 0.60 −2.15 −12.57
    PC 40° C. wt % 4.20 4.09 4.08 4.07 3.61
    Nicotine
    % loss −2.66 −2.84 −3.16 −14.10
  • As can be seen from the above Table, polypropylene (PP) and polycarbonate (PC) both of which are desirable materials for use in e-cigarettes were found to result in significant loss of nicotine when stored in contact with a nicotine solution containing nicotine only in free base form.
  • Example 4 Storage Stability of Protonated Nicotine in e-cigarettes
  • The effect on storage stability of protonating nicotine was studied by examining 3 nicotine solutions loaded into cartomizer e-cigarettes (“Device”) containing PP and PC. The three nicotine solutions were an acid free nicotine solution and two protonated solutions, one protonated with 1.0 Molar equivalent levulinic acid and one protonated with 1.0 Molar equivalent benzoic acid. For each of the formulations manufactured a 2.5% w/w nicotine amount was used, together with 9% water and sufficient glycerol to make the solution to 100%. The stability protocol incorporated filling a series of e-cigarettes for each formulation, as well as loading a number of sealed glass vials (used as control samples) to understand the source of any observed nicotine losses.
  • Over the duration of the study samples were stored at 25 deg Celsius/60% relative humidity and 40 deg Celsius/75% relative humidity for a total of 9 weeks, data was collected at time points 1, 5 and 9 weeks. During the study time the e-cigarette solution was in contact with the internal materials of the cartomizer (including PP and PC) in a manner reflecting real-world use. In the table below, T0=1 week, T4=5 Weeks and T8=9 Weeks.
  • At each of the above time points the amount of nicotine present within formulation was determined as follows.
  • For analysis of e-liquids: approximately 100 μl liquid was extracted into 20 ml extraction solvent and analyzed as described for aerosol determination.
  • The e-cigarettes were puffed on a 20-channel linear smoking machine (SM450) compliant with ISO 3308, but using the following puffing parameters: 80 ml puff volume, 3 second puff duration and 30 second interpuff interval. Each port of the smoking engine was fitted with a holder containing a Cambridge filter (CF) pad to trap particulate matter. After puffing TPM was determined as the weight difference of the CF before and after puffing, in accordance with ISO 4387. The CF pad containing trapped aerosol was extracted into 20 ml high purity propan-2-ol containing appropriate internal standards. Nicotine and water were determined by GC analysis containing combined FID/TCD detectors.
  • The data below reports the nicotine levels measured.
  • T0 (25° C./60% RH)
    Nicotine (% w/w)
    Formulation Vial Device
    Standard 2.36 2.11
    +Levulinic 2.35 2.29
    Acid
    +Benzoic 2.37 2.31
    Acid
    T4 (25° C./60% RH)
    Nicotine (% w/w)
    Formulation Vial Device
    Standard 2.49 1.48
    +Levulinic 2.51 2.03
    Acid
    +Benzoic 2.53 2.12
    Acid
    T4 (40° C./75% RH)
    Nicotine (% w/w)
    Formulation Vial Device
    Standard 2.49 0.94
    +Levulinic 2.5  1.68
    Acid
    +Benzoic 2.52 1.8 
    Acid
    T8 (25° C./60% RH)
    Nicotine (% w/w)
    Formulation Vial Device
    Standard 2.42 0.94
    +Levulinic 2.4  1.55
    Acid
    +Benzoic 2.43 1.7 
    Acid
    T8 (40° C./75% RH)
    Nicotine (% w/w)
    Formulation Vial Device
    Standard 2.41 0.18
    +Levulinic 2.44 0.96
    Acid
    +Benzoic 2.44 1.2 
    Acid
  • Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.

Claims (21)

1. (canceled)
2. An electronic vapor provision system according to claim 11 wherein a majority of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
3. An electronic vapor provision system according to claim 11 wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate.
4. An electronic vapor provision system according to claim 11 wherein at least a portion of the container in contact with the nicotine solution is formed from polypropylene.
5. (canceled)
6. An electronic vapor provision system according to claim 11 wherein at least 20 wt % of the nicotine present in the solution is in protonated form.
7. An electronic vapor provision system according to claim 11 wherein at least 40 wt % of the nicotine present in the solution is in protonated form.
8. An electronic vapor provision system according to claim 11 wherein the nicotine is protonated by an acid selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
9. An electronic vapor provision system according to claim 1 wherein the nicotine is protonated by levulinic acid.
10. An electronic vapor provision system according to claim 11 wherein the nicotine is protonated by benzoic acid.
11. An electronic vapor provision system comprising:
a vaporizer for vaporizing liquid for inhalation by a user of the electronic vapor provision system;
a power supply comprising a cell or battery for supplying power to the vaporizer; and
a container in which is contained a nicotine solution, wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
12-23. (canceled)
24. A cartomizer for an electronic vapor provision system, wherein the cartomizer comprises:
a container in which is contained a nicotine solution;
a wick material; and
a heating element for vaporizing the nicotine;
wherein at least 5 wt % of the nicotine present in the solution is in protonated form, and wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
25. A cartomizer according to claim 24 wherein a majority of the container in contact with the nicotine solution is formed from polycarbonate or polypropylene.
26. A cartomizer according to claim 24 wherein at least a portion of the container in contact with the nicotine solution is formed from polycarbonate.
27. A cartomizer according to claim 24 wherein at least a portion of the container in contact with the nicotine solution is formed from polypropylene.
28. A cartomizer according to claim 24 wherein at least 20 wt % of the nicotine present in the solution is in protonated form.
29. A cartomizer according to claim 24 wherein at least 40 wt % of the nicotine present in the solution is in protonated form.
30. A cartomizer according to claim 24 wherein the nicotine is protonated by an acid selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, oleic acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
31. A cartomizer according to claim 24 wherein the nicotine is protonated by levulinic acid.
32. A cartomizer according to claim 24 wherein the nicotine is protonated by benzoic acid.
US15/525,163 2014-11-07 2015-11-06 Container containing a nicotine solution Pending US20180228214A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1419866.7A GB2532062A (en) 2014-11-07 2014-11-07 Container
GB1419866.7 2014-11-07
PCT/GB2015/053369 WO2016071706A1 (en) 2014-11-07 2015-11-06 Container containing a nicotine solution

Publications (1)

Publication Number Publication Date
US20180228214A1 true US20180228214A1 (en) 2018-08-16

Family

ID=52118166

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/525,163 Pending US20180228214A1 (en) 2014-11-07 2015-11-06 Container containing a nicotine solution

Country Status (20)

Country Link
US (1) US20180228214A1 (en)
EP (4) EP3491941B1 (en)
JP (1) JP6450002B2 (en)
KR (2) KR102035196B1 (en)
CN (2) CN109965357B (en)
AR (2) AR102579A1 (en)
AU (1) AU2015341517B2 (en)
BR (1) BR112017009258B1 (en)
CA (1) CA2964829C (en)
CL (1) CL2017001137A1 (en)
ES (2) ES2832751T3 (en)
GB (1) GB2532062A (en)
HU (2) HUE044286T2 (en)
MX (2) MX2017005939A (en)
MY (1) MY198202A (en)
PH (1) PH12017500837A1 (en)
PL (2) PL3491941T3 (en)
RU (2) RU2695839C2 (en)
TR (1) TR201904005T4 (en)
WO (1) WO2016071706A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021035103A1 (en) * 2019-02-15 2021-02-25 Bn Intellectual Properties, Inc. Nicotine formulation for active mesh nebulizer
WO2022180491A1 (en) * 2021-02-24 2022-09-01 Rai Strategic Holdings, Inc. Aerosol precursor formulations
US11583003B2 (en) 2018-10-12 2023-02-21 Rai Strategic Holdings, Inc. Connectors for forming electrical and mechanical connections between interchangeable units in an aerosol delivery system
US11588287B2 (en) 2018-10-12 2023-02-21 Rai Strategic Holdings, Inc. Aerosol delivery device with improved connectivity, airflow, and aerosol paths
US11678700B2 (en) 2018-10-12 2023-06-20 Rai Strategic Holdings, Inc. Aerosol delivery device with visible indicator
US11974603B2 (en) 2018-10-12 2024-05-07 Rai Strategic Holdings, Inc. Aerosol delivery device with visible indicator

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160345631A1 (en) 2005-07-19 2016-12-01 James Monsees Portable devices for generating an inhalable vapor
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
PL2672847T3 (en) 2011-02-11 2015-10-30 Batmark Ltd Inhaler component
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
IL297399B2 (en) 2013-05-06 2024-02-01 Juul Labs Inc Nicotine salt formulations for aerosol devices and methods thereof
CN113142679A (en) 2013-12-05 2021-07-23 尤尔实验室有限公司 Nicotine liquid formulations for aerosol devices and methods thereof
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US9549573B2 (en) 2013-12-23 2017-01-24 Pax Labs, Inc. Vaporization device systems and methods
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
GB2560651B8 (en) 2013-12-23 2018-12-19 Juul Labs Uk Holdco Ltd Vaporization device systems and methods
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
WO2015175979A1 (en) 2014-05-16 2015-11-19 Pax Labs, Inc. Systems and methods for aerosolizing a smokeable material
US9896429B2 (en) 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US10508096B2 (en) 2014-05-27 2019-12-17 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
WO2015183801A1 (en) 2014-05-27 2015-12-03 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2532062A (en) 2014-11-07 2016-05-11 Nicoventures Holdings Ltd Container
RU2709926C2 (en) 2014-12-05 2019-12-23 Джуул Лэбз, Инк. Calibrated dose control
MX2018009703A (en) 2016-02-11 2019-07-08 Juul Labs Inc Securely attaching cartridges for vaporizer devices.
UA125687C2 (en) 2016-02-11 2022-05-18 Джуул Лебз, Інк. Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
US11660403B2 (en) 2016-09-22 2023-05-30 Juul Labs, Inc. Leak-resistant vaporizer device
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
US12114688B2 (en) 2017-10-24 2024-10-15 Rai Strategic Holdings, Inc. Method for formulating aerosol precursor for aerosol delivery device
CN109171010A (en) * 2018-09-10 2019-01-11 深圳市新宜康科技股份有限公司 Liquid nicotine salt and preparation method thereof
GB201817861D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
US11992038B2 (en) 2018-12-31 2024-05-28 Philip Morris Products S.A. Liquid nicotine formulation comprising partially water-soluble solvent
CN113840545A (en) * 2019-05-31 2021-12-24 日本烟草国际股份有限公司 Nicotine liquid formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076289A2 (en) * 2003-02-28 2004-09-10 Pfizer Health Ab A container comprising nicotine and the use and manufacture thereof
EP1618803A1 (en) * 2003-04-29 2006-01-25 Lik Hon A flameless electronic atomizing cigarette
US20060018840A1 (en) * 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
US20140345635A1 (en) * 2013-05-22 2014-11-27 Njoy, Inc. Compositions, devices, and methods for nicotine aerosol delivery

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502132A (en) * 1975-05-27 1978-02-22 Ici Ltd Smoking materials
GB2133691B (en) * 1983-01-21 1986-05-21 Leo Ab Smoking substitutes for nasal administration
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4800903A (en) * 1985-05-24 1989-01-31 Ray Jon P Nicotine dispenser with polymeric reservoir of nicotine
DE3884246T2 (en) * 1987-02-10 1994-03-03 Reynolds Tobacco Co R Cigarette.
US5031646A (en) * 1990-01-16 1991-07-16 R. J. Reynolds Tobacco Company Cigarette
DE69531488T2 (en) 1994-03-07 2004-06-17 Theratech Inc., Salt Lake City MEDICINE-CONTAINING, ADHESIVE, ASSEMBLABLE, TRANSDERMAL DISPENSER
SE9900215D0 (en) * 1999-01-26 1999-01-26 Pharmacia & Upjohn Ab New use
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
JP2004512907A (en) * 2000-11-03 2004-04-30 リカバリー ファーマシューティカルズ インコーポレーティッド Device and method for smoking cessation
JP2003024036A (en) * 2001-07-18 2003-01-28 Ikeda Denki Seisakusho:Kk Smoking-prohibiting tool
US7767698B2 (en) * 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
SE0201669D0 (en) * 2002-06-03 2002-06-03 Pharmacia Ab New formulation and use thereof
US20040182403A1 (en) 2003-02-28 2004-09-23 Sven-Borje Andersson Container comprising nicotine and the use and manufacture thereof
CN2719043Y (en) 2004-04-14 2005-08-24 韩力 Atomized electronic cigarette
CN101437496A (en) * 2006-03-16 2009-05-20 尼科诺瓦姆股份公司 Chewing gum compositions providing rapid release of nicotine
US8657843B2 (en) 2006-05-03 2014-02-25 Applied Medical Resources Corporation Shield lockout for bladed obturator and trocars
CN201067079Y (en) * 2006-05-16 2008-06-04 韩力 Simulation aerosol inhaler
US7726320B2 (en) * 2006-10-18 2010-06-01 R. J. Reynolds Tobacco Company Tobacco-containing smoking article
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
IN2012DN02325A (en) * 2009-09-16 2015-08-21 Philip Morris Products Sa
AT509046B1 (en) * 2010-03-10 2011-06-15 Helmut Dr Buchberger FLAT EVAPORATOR
SE535587C2 (en) * 2011-03-29 2012-10-02 Chill Of Sweden Ab Product containing a free nicotine salt and a non-water-soluble bag
US9351522B2 (en) 2011-09-29 2016-05-31 Robert Safari Cartomizer e-cigarette
US9282772B2 (en) 2012-01-31 2016-03-15 Altria Client Services Llc Electronic vaping device
US10004259B2 (en) 2012-06-28 2018-06-26 Rai Strategic Holdings, Inc. Reservoir and heater system for controllable delivery of multiple aerosolizable materials in an electronic smoking article
US20140261486A1 (en) 2013-03-12 2014-09-18 R.J. Reynolds Tobacco Company Electronic smoking article having a vapor-enhancing apparatus and associated method
US20140261474A1 (en) 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine
US10799548B2 (en) 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
GB2513637A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
IL297399B2 (en) 2013-05-06 2024-02-01 Juul Labs Inc Nicotine salt formulations for aerosol devices and methods thereof
KR102378679B1 (en) 2013-12-19 2022-03-28 필립모리스 프로덕츠 에스.에이. Aerosol-generating system for generating and controlling the quantity of nicotine salt particles
US9955726B2 (en) 2014-05-23 2018-05-01 Rai Strategic Holdings, Inc. Sealed cartridge for an aerosol delivery device and related assembly method
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2532062A (en) 2014-11-07 2016-05-11 Nicoventures Holdings Ltd Container

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076289A2 (en) * 2003-02-28 2004-09-10 Pfizer Health Ab A container comprising nicotine and the use and manufacture thereof
EP1618803A1 (en) * 2003-04-29 2006-01-25 Lik Hon A flameless electronic atomizing cigarette
US20060018840A1 (en) * 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
US20140345635A1 (en) * 2013-05-22 2014-11-27 Njoy, Inc. Compositions, devices, and methods for nicotine aerosol delivery

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583003B2 (en) 2018-10-12 2023-02-21 Rai Strategic Holdings, Inc. Connectors for forming electrical and mechanical connections between interchangeable units in an aerosol delivery system
US11588287B2 (en) 2018-10-12 2023-02-21 Rai Strategic Holdings, Inc. Aerosol delivery device with improved connectivity, airflow, and aerosol paths
US11677201B2 (en) 2018-10-12 2023-06-13 Rai Strategic Holdings, Inc. Aerosol delivery device with improved connectivity, airflow, and aerosol paths
US11678700B2 (en) 2018-10-12 2023-06-20 Rai Strategic Holdings, Inc. Aerosol delivery device with visible indicator
US11856988B2 (en) 2018-10-12 2024-01-02 Rai Strategic Holdings, Inc. Connectors for forming electrical and mechanical connections between interchangeable units in an aerosol delivery system
US11967793B2 (en) 2018-10-12 2024-04-23 Rai Strategic Holdings, Inc. Aerosol delivery device with improved connectivity, airflow, and aerosol paths
US11974603B2 (en) 2018-10-12 2024-05-07 Rai Strategic Holdings, Inc. Aerosol delivery device with visible indicator
WO2021035103A1 (en) * 2019-02-15 2021-02-25 Bn Intellectual Properties, Inc. Nicotine formulation for active mesh nebulizer
WO2022180491A1 (en) * 2021-02-24 2022-09-01 Rai Strategic Holdings, Inc. Aerosol precursor formulations

Also Published As

Publication number Publication date
ES2718222T3 (en) 2019-06-28
AU2015341517A1 (en) 2017-05-04
HUE044286T2 (en) 2019-10-28
AU2015341517B2 (en) 2018-01-18
CN107072287A (en) 2017-08-18
PH12017500837B1 (en) 2017-10-30
MX2017005939A (en) 2017-07-19
CN109965357A (en) 2019-07-05
KR101984834B1 (en) 2019-05-31
CN107072287B (en) 2019-02-26
AR118187A2 (en) 2021-09-22
TR201904005T4 (en) 2019-04-22
CA2964829A1 (en) 2016-05-12
GB201419866D0 (en) 2014-12-24
BR112017009258A2 (en) 2018-01-30
GB2532062A (en) 2016-05-11
EP4430961A2 (en) 2024-09-18
CL2017001137A1 (en) 2018-01-05
RU2019100397A (en) 2019-02-05
KR20170066568A (en) 2017-06-14
RU2017115501A3 (en) 2018-11-06
KR20190058719A (en) 2019-05-29
RU2019100397A3 (en) 2019-05-22
WO2016071706A1 (en) 2016-05-12
CA2964829C (en) 2024-04-02
KR102035196B1 (en) 2019-10-22
RU2017115501A (en) 2018-11-06
EP3491941B1 (en) 2020-08-12
ES2832751T3 (en) 2021-06-11
JP6450002B2 (en) 2019-01-09
AR102579A1 (en) 2017-03-08
HUE051844T2 (en) 2021-03-29
EP3738447B1 (en) 2024-09-11
PH12017500837A1 (en) 2017-10-30
EP3491941A1 (en) 2019-06-05
RU2677847C2 (en) 2019-01-21
EP3214957B1 (en) 2019-02-13
PL3214957T3 (en) 2019-07-31
MY198202A (en) 2023-08-11
EP3214957A1 (en) 2017-09-13
BR112017009258B1 (en) 2022-05-03
EP3738447A1 (en) 2020-11-18
CN109965357B (en) 2022-09-30
JP2017532968A (en) 2017-11-09
RU2695839C2 (en) 2019-07-29
MX2023011896A (en) 2023-10-18
PL3491941T3 (en) 2021-06-14

Similar Documents

Publication Publication Date Title
US20180228214A1 (en) Container containing a nicotine solution
US20210045428A1 (en) Solution comprising nicotine in unprotonated form and protonated form

Legal Events

Date Code Title Description
AS Assignment

Owner name: NICOVENTURES HOLDINGS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCADAM, KEVIN GERARD;BRUTON, CONNOR;TRANI, MARINA;SIGNING DATES FROM 20170523 TO 20170524;REEL/FRAME:045875/0771

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: NICOVENTURES TRADING LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NICOVENTURES HOLDINGS LIMITED;REEL/FRAME:055424/0056

Effective date: 20200305

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: APPEAL READY FOR REVIEW

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS